Silicon preparations for modulating gut flora to improve cholesterol metabolism and methods of making the same

By preparing a silicon-based preparation to regulate gut microbiota and utilizing pharmaceutical-grade water-soluble silica to regulate cholesterol metabolism, the problem of side effects of existing drugs has been solved, achieving a safe and effective cholesterol improvement effect.

CN122163642APending Publication Date: 2026-06-09GUANGDONG SILICON PLANT TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN Β· China
Patent Type
Applications(China)
Current Assignee / Owner
GUANGDONG SILICON PLANT TECHNOLOGY CO LTD
Filing Date
2026-03-27
Publication Date
2026-06-09

AI Technical Summary

Technical Problem

Existing cholesterol-lowering drugs have side effects with long-term use, such as muscle toxicity and new-onset diabetes, and have poor adherence. Current technology has not been able to systematically study the gut microbiota-mediated mechanism of water-soluble silica in regulating cholesterol metabolism.

Method used

Using pharmaceutical-grade water-soluble silica as raw material, the weight ratio of metasilicic acid to silica is controlled at 1.3~1.5:1, and the pH value after dilution is 6.5~7.5. Low-dose and high-dose silica preparations are prepared in the form of oral liquid, solid beverage or dietary supplement, which improve cholesterol metabolism by regulating the balance of intestinal flora.

Benefits of technology

It has achieved safe and effective reduction of plasma total cholesterol, triglycerides, non-high-density lipoprotein cholesterol and liver cholesterol levels, inhibited atherosclerotic plaques, promoted the excretion of cholesterol metabolites, increased the abundance of beneficial bacteria, and reduced the risk of cardiovascular disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122163642A_ABST
    Figure CN122163642A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of pharmaceutical technology, and particularly relates to a silicon-based preparation for regulating intestinal flora to improve cholesterol metabolism and its preparation method. The method includes: S1, providing pharmaceutical-grade water-soluble silica raw material; S2, diluting the water-soluble silica raw material with sterile deionized water, stirring at 100-200 r / min for 10-20 min at 20-25Β°C, and preparing low-dose and high-dose silicon-based preparations respectively. This invention addresses the shortcomings of existing cholesterol-lowering drugs, such as muscle toxicity and new-onset diabetes, caused by long-term use, by providing a silicon-based preparation using pharmaceutical-grade water-soluble silica as a raw material. By limiting the content of metasilicic acid and silica in the raw material, controlling the heavy metal impurity content to ≀10 ppm, and combining sterile deionized water dilution with precise stirring conditions and pH control, the high purity and stability of the preparation are ensured.
Need to check novelty before this filing date? Find Prior Art